Diagnosis → Ophthalmology

Glaucoma

A progressive optic neuropathy with or without visual field defects, often in conjunction with elevated intraocular pressure ≥ 21 mmHg.

Etiology

Causes [wpc]

  1. Primary open-angle glaucoma (POAG): most common

    • Increased resistance to aqueous outflow --> Ineffective drainage system

    • Rise in IOP --> Reduced blood flow to the optic nerve

    • Slow and painless damage to the optic nerve

    • Characteristic damage patterns in the visual field and the optic nerve:

      • Loss of peripheral vision in one or typically both eyes

      • Eventually loss of central vision (permanent and irreversible)

  2. Primary angle-closure glaucoma (PACG): 10% of glaucoma cases

    • Darkness/drugs --> pupillary dilatation --> thick iris

    • Age-related lens thickening --> pushes the iris anteriorly

    • Closure of the angle formed between the cornea and the iris

    • Blockage of the outflow tract --> IOP rapidly increases

      • Blurry vision

      • Corneal edema

      • Eye pain

      • Headache

      • Nausea

      • Emesis

  3. Secondary glaucoma arises due to obstruction/damage to trabecular meshwork

    • Lens subluxation in Marfan syndrome

    • Irregular corneal endothelium migration onto the trabecular meshwork

    • Neovascularization (retinal artery/vein occlusion, proliferative diabetic retinopathy)

    • Peripheral anterior synechiae

    • Eye injury

    • Post-ophthalmic surgery (ciliary body edema)

    • Sulfa drugs --> ciliochoroidal effusion

    • Pseudoexfoliation (flaky material within the anterior chamber that clog the trabecular meshwork)

    • Pigment dispersion syndrome (pigment granules from the posterior iris surface)

    • Steroid-induced glaucoma

    • Carotid-cavernous fistula

    • Ellingson syndrome (uveitis-glaucoma-hyphema syndrome)

    • Glaucomatocyclitic crisis (Posner-Schlossman syndrome)

    • Inflammatory glaucoma: Uveitis/iridocyclitis

  4. Normal-tension glaucoma

    • Optic nerve damage due to normal pressure, atherosclerosis or vascular insufficiency

    • Associated with migraines, Raynaud phenomenon, autoimmune diseases, ischemic vascular diseases, and coagulopathies

  5. Congenital/infantile glaucoma

    • Affects individuals between the ages of 1 and 36 months

    • Trabeculodysgenesis

    • Anterior segment dysgenesis

Pathophysiology [wpc]

Risk factors [wpc]

Complications

Epidemiology

Incidence per 100.000 [bie][pon]

Default

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Blindness, Blurred vision, Headache, Nausea, Red eye, Scotoma, Visual disturbances, Vomiting

Clinical findings

None listed.

Anamneses

None listed.

Localized findings

Pain
Radiates
Eyes
Onset
Acute (minutes)Subacute (hours)Gradual (days)
Pattern
IntermittentConstant
Severity
Mild (1-3)Moderate (4-7)

Approach

Diagnostic criteria

Treatment

  1. Goal: impossible to reverse vision loss. Treatment aims to lower IOP [wpc]

  2. Medications: [wpc][ihy]

    • Prostaglandin analogs

    • β-blockers

    • Carbonic anhydrase inhibitors

    • α-2 agonists

    • Miotic agents

    • Rho-kinase inhibitors

    • Nitric oxide-donating medications

    • Hyperosmotic agents (isosorbide dinitrate, mannitol, glycerin)

  3. Laser:

    • Laser trabeculoplasty: benefits last months, and retreatments are necessary

    • Laser ablation of the ciliary body to reduce aqueous production

    • Laser peripheral iridotomy (acute angle-closure glaucoma)

  4. Surgery:

    • Trabeculectomy

    • Deep sclerectomy

    • Canaloplasty

    • Insertion of a drainage valve/tube shunt

    • Minimally invasive glaucoma surgery (MIGS) [ihy]

      • Deep sclerectomy/viscocanalostomy

      • 360-degree suture canaloplasty

      • Trabectome

      • Endoscopic cyclophotocoagulation (ECP)

      • iStent implant

      • Gonioscopy-assisted transluminal trabeculotomy (GAAT)

      • Kahook dual blade

      • Xen Gel Implant

Differential diagnoses

Cluster headache, Conjunctivitis, Corneal abrasion, Corneal ulcer, Endophthalmitis, Episcleritis, Hyphema, Iridocyclitis, Keratitis, Migraine, Optic neuritis, Periorbital cellulitis, Subconjunctival hemorrhage


References

[1] Dietze J, Blair K, Zeppieri M, et al. Glaucoma. [Updated 2024 Mar 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538217/

[2] Velez-Nandayapa L, Eggenschwiler L, Jick SS, Meier CR, Becker C. The incidence rates and prevalence of treated glaucoma in the United Kingdom, 2000-2022. PLoS One. 2026 Sep 3;21(9):e0354463.

[3] Shan S, Wu J, Cao J, Feng Y, Zhou J, Luo Z, Song P, Rudan I; Global Health Epidemiology Research Group (GHERG). Global incidence and risk factors for glaucoma: A systematic review and meta-analysis of prospective studies. J Glob Health. 2024 Nov 8;14:04252.

[4] https://emedicine.medscape.com/article/1206147 (12th September 2026)

Scroll to top